RNA sequencing (RNA-Seq), a revolutionary tool for transcriptome profiling, is becoming increasingly important for neuroscientists in studying the transcriptional landscape of the human brain. Studies using this next-generation sequencing technique have already revealed novel insights into the complexity of neurons in the human brain and pathogenesis of complex neurological diseases. In clinical neuroscience, RNA-Seq provides exciting opportunities for improving diagnosis and treatment of neurological diseases by facilitating the development of pharmacotherapies able to modulate gene expression. Furthermore, integrative whole genome sequencing and transcriptome sequencing can provide additional information for the functional role of mutated genes, prioritization of variants, and intron/exon splicing. This review describes the current state of RNA-Seq studies in neuropsychiatric disorders using post-mortem human brains, a brief survey of best practices for experimental design and sequencing data analysis, and the challenges associated with its application in the human brain.
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T HE STUDY OF neuropsychiatric disorders is an intricate task, especially for complex diseases, such as schizophrenia, bipolar disorder (BD), and addiction. These diseases are not caused by a single gene mutation, but by dysfunction of multiple genes or gene networks, and the links between these mutations and disease onset remain poorly elucidated.
Whole genome/exome sequencing and single nucleotide polymorphisms (SNP) array have significantly improved the identification of genome-wide associated SNP and copy number variations (CNV) linked to neuropsychiatric diseases. 1 Current genetic knowledge, however, does not provide comprehensive understanding into the functional role of DNA mutations to disease onset. In this scenario, transcriptome profiling studies are increasingly gaining attention among neuroscientists.
Global gene expression studies provide a highthroughput method for the identification of genes and gene networks associated with complex brain disorders. Advances in these high-throughput technologies over the past two decades have led to novel insights into the pathophysiology of brain disorders. Until recently, the microarray has represented the most powerful tool to investigate gene expression changes; 2, 3 however, the microarray relies on an indirect quantification by hybridization, leading to several limitations: high background due to cross-hybridization; 4 required a priori knowledge of sequences being studied; and small dynamic ranges of abundance.
Over the past few years, RNA-Seq has gained increasing popularity and supplanted microarrays as the primary high-throughput choice for quantifying the whole transcriptome.
5 RNA-Seq is based on next-generation sequencing that directly determines the cDNA sequence. It effectively surmounts the limitations of microarray: a priori sequence knowledge is not required; different layers including exon-, isoform-and gene-level quantification can be performed; and large dynamic range can be obtained. 6 As the human brain exhibits a more diverse splicing program than other tissues, 7 RNA-Seq technology has become an ideal tool to interrogate the role of splicing events as well as transcriptomic changes in the development of neurological disorders.
Advances in large-scale RNA-Seq data analyses have already led to a detailed atlas of the human brain transcriptome. The Genotype and Tissue Expression (GTEx) project of the NIH Common Fund provides a comprehensive RNA-Seq transcriptomic profile in a total of 13 brain regions from control subjects. 7 The current v6 release (dbGaP Accession phs000424.v6.p1) contains 1259 RNASeq profiles in brain regions including the amygdala, anterior cingulate cortex, caudate, cerebellar hemisphere, cerebellum, cortex, frontal cortex, hippocampus, hypothalamus, nucleus accumbens, putamen, spinal cord, and substantia nigra. These post-mortem brain tissues were sequenced by using Illumina HiSeq 2000, which employed a 76-bp, paired-end Illumina TruSeq RNA protocol, producing an average of 50 million aligned reads per sample. The GTEx study indicated that the brain exhibits a more divergent splicing program compared to other peripheral tissues. 7 More importantly, the GTEx provides an opportunity to assess human gene expression signatures in the brain through crosstissue analysis of gene expression in control subjects.
In the present review, we describe current applications of whole transcriptome RNA-Seq to the study of neuropsychiatric disorders in post-mortem human brains and also discuss methodological considerations for the acquisition of well-characterized post-mortem brain samples and execution of RNA-Seq analyses.
HUMAN BRAIN SPECIMENS
Our understanding of biological mechanisms of many neuropsychiatric diseases, such as addiction and schizophrenia, remain frustratingly limited. 8 Access to post-mortem human brain samples enables a direct investigation of these diseases, specifically assessing the neurobiological changes at the molecular, cellular, and synaptic levels. 9 Thus, the availability of human brain specimens has become increasingly critical, especially in light of the recent advances of high-throughput techniques, such as RNA-Seq. Although brain tissues of diseased patients and healthy controls are relatively limited at early stages, numerous efforts have been made internationally over the past few decades to remedy this problem. 10, 11 More than 20 brain banks have been established in Europe, the USA, Australia, and Asia to support brain disease research, 12, 13 and through global communication and collaboration, these banks have enabled a more efficient approach for the collection, storage, and distribution of brain specimens and the data collected from these specimens to neuroscientists worldwide. For example, BrainNet Europe brings together 19 brain banks throughout Europe with each individual bank specializing in specific brain disorders. Thus far, access to postmortem healthy and diseased brain tissue has advanced our understanding of brain disorder pathophysiology as well as improved therapeutics development for human neurological disorders.
RNA-SEQ IN HUMAN BRAINS OF NEUROPSYCHIATRIC DISORDERS
RNA studies in post-mortem brains have long been used to investigate gene expression changes between normal and diseased conditions. [14] [15] [16] [17] [18] [19] Table 1 summarizes recent RNA-Seq studies of neuropsychiatric disorders using post-mortem human brain tissues.
14-23
-23 RNA-Seq provides an ideal tool not only to examine global expression changes but also to identify novel splicing events and their link to disease, even identifying neuronal cell types using single-cell RNA sequencing. 24 By using RNA-Seq and ChIP sequencing, Zhou et al. revealed gene expression changes between both cocaine-addicted and alcoholic post-mortem brains and their respective controls in common hippocampal genes, including CDR1, LRCH4, CACNB2, FAM123A, HIST1H4E, PAPD1, HNRPH1, ZGPAT, ERF, and HIVEP3.
14 These shared neuronal function-associated molecular changes in the hippocampus reflect a common trait of neuronal adaptations in both types of addictions. A transcriptomic study on chronic alcohol abuse by Farris et al.
demonstrated multiple ion channels and related processes in the human prefrontal cortex linked to extended alcohol abuse. 21 Wu et al. performed the first RNA-Seq profiling of the superior temporal gyrus (STG) from schizophrenia subjects. 20 They identified three functional clusters in the STG that were strongly linked to schizophrenia, including synaptic vesicle trafficking, neurotransmissionrelated functions, and neural development. Hwang et al. identified 144 differentially expressed (DE) genes in the post-mortem hippocampus of schizophrenic subjects through RNA-Seq. 17 Their results showed that upregulation of immune/inflammation genes, such as IFITM1, IFITM2, IFITM3, APOL1, ADORA2A, IGFBP4, and CD163, may contribute to the pathophysiology of schizophrenia. RNA-Seq analysis from the study by Sinclair et al. revealed abnormal expression of FKBP5, PTGES3, BAG1, and glucocorticoid receptor genes in the prefrontal cortex in both schizophrenia and BD subjects. 15 Another RNA-Seq study showed altered expression of gene transcripts involved in neuroplasticity, such as PROM1, ABCG2, and FLI1, and circadian rhythms, such as OSBPL3, GANAB, SRSF5, and RFX4, in the dorsolateral prefrontal cortex of individuals with BD. 19 Moreover, GWAS enrichment analysis indicated that genes involved in GTPase binding may play an important role in BD. Kohen et al. performed the first RNA-Seq survey of transcriptome in dentate gyrus granule cells isolated from subjects with mental illnesses, such as schizophrenia, BD, and major depression. 16 They found disrupted hippocampal miR-182 signaling in these post-mortem brains compared to controls. Another recent RNASeq study identified three DE genes in the anterior cingulate in BD patients, RXFP1, SSTR2, and CHRM2, that belong to class A of the G proteincoupled receptor family, 18 suggesting dysregulation of G protein-coupled receptors in BD. A more recent study by Pacifico and Davis investigated the transcriptome profiles of the dorsal striatum from BD subjects. 23 They identified dorsal striatum-specific immune response and oxidative phosphorylation pathways for BD. Moreover, Yin et al. studied the GABA and glutamate neurotransmitter systems in dorsolateral prefrontal cortex of major depressive disorder and suicide cases. They performed an integrative analysis of genotypes and transcriptome profiling and indicated a downregulation of GABRG2 in suicide cases and identified an SNP (ra424740) for association with suicide death. 22 Thus, RNA-Seq technology provides a powerful tool for the transcriptomic study of post-mortem brain tissues and for the identification of novel targets that may play a role in the pathophysiology of neuropsychiatric disorders. However, experimental protocols pertaining to human brain tissues, RNASeq assays, and downstream bioinformatics analysis differ quite dramatically from one study to the next. Minimizing these technological and biological biases is a crucial task to better understand the pathogeneses of neuropsychiatric disorders. This review will therefore aim to address important considerations for the acquisition and interpretation of RNA-Seq data.
METHODOLOGICAL CONSIDERATION OF RNA-SEQ STUDY DESIGN
Diagnostic reliability, tissue, and RNA quality A critical factor in post-mortem brain research is the reliability of disease diagnoses. 25 Medical record reviews and post-mortem family interviews are the two most commonly used approaches for confirmation of diagnosis of cases and matched non-diseased controls. Another important clinical quality control is agonal factors, defined as the specific agonal, or pain, conditions and agonal duration. 26 It was reported that the similarity between gene expression profiles is decreased by agonal factors. 26 Tomita et al. showed that agonal factors influence microarray gene expression profiles more than post-mortem factors or other biological factors. 26 However, there is currently no consensus about how to evaluate agonal factors. Brain pH is negatively correlated with the agonal state, 26 thus it can be served as a more objective measure of clinical and tissue quality. Certain selection criteria, such as brain pH > 6.0, can be adopted to ensure the clinical quality of each case.
14 Post-mortem factors, including post-mortem interval and freezer interval, are also major factors that could affect RNA integrity. It was shown that RNA degradation is dependent on post-mortem interval. 27 Furthermore, RNA polyA tail seems to be affected by longer freezer interval. 28 Freeze-thaw cycles may also accelerate RNA degradation.
Biological factors, including age, sex, and race, are possible cofounding factors and should be matched in typical case-control studies. 29, 30 A large number of age-associated genes have been reported in either microarray or RNA-Seq gene expression profiles of the human brain, 31, 32 and sex and race have been suggested to cause bias in gene expression changes. 33 Well-matched non-diseased controls will significantly reduce confounding bias caused by these factors.
RNA quality is another critical factor that will affect subsequent RNA-Seq assays. RNA integrity number (RIN), 34 an algorithm for assigning integrity values to RNA measurements, has been widely used for evaluating the quality of RNA-Seq samples. Lower RIN may lead to skewed gene expression profiles. 35 Although no consensus exists for the cut-off of RIN in RNA-Seq, a stringent protocol to evaluate RNA integrity will improve the quality of RNA-Seq data and interpretation.
RNA-Seq assays
When performing RNA-Seq, total RNA is isolated from brain tissues of interest. To study mRNA species, pretreatment with oligo-dT beads to capture polyA tails or depleting ribosomal RNA (rRNA) is required. mRNA are then converted into a library of cDNA fragments, and sequence adaptors are added to each end of the resulting molecule. Small-and microRNA purification gives the possibility to detect other specific RNA species. Current next-generation sequencing platforms include the Illumina Genome Analyzer/HiSeq system, the Applied Biosystems SOLiD system, and the Roche 454 system. 36 Sequencing depth is one of the most important factors in designing the RNA-Seq assays. Optimal sequencing depth depends on the goals of the study. For identifying differentially expressed genes between two groups in human tissues, only modest depths of sequencing may be needed (e.g., 30M reads). For studies aiming to identify novel transcripts/isoforms or detecting genes that have low expression levels, more extensive sequencing (>80M reads) is required. 37, 38 The Encyclopedia of DNA elements (ENCODE) consortium showed that 80% of transcripts with expression levels >10 fragments per kilobase of transcript per million reads mapped can be accurately measured using~36M mapped reads. 39 The number of replicates depends on the technical variability of RNA-Seq, biological variability of the case-control studies, and statistical power. Hart et al. provided a reference for calculating optimal sample size, sequencing depth, and power. 40 Given a fixed budget, optimal sequencing depth and number of biological replicates may be evaluated to ensure the identification of DE genes from RNA-Seq experiments. For example, a recent RNA-Seq study in post-mortem tissues from the anterior cingulate cortex of 13 BD subjects and 13 matched controls revealed 10 DE genes at the level of false discovery rate < 0.05. 18 In this study, Cruceanu et al. generated 391M mapped 100-bp reads by using the HiSeq200 platform. The ribosomal depletion approach and sequence depth allowed the detection of non-polyAtailed RNA. Nevertheless, no DE isoforms were identified in this study. Limited sample size may reduce the statistical power in differential expression analyses.
BIOINFORMATICS ANALYSIS
There is no gold standard regarding the optimal RNASeq analyses pipeline. Researchers adopt different RNA-Seq pipelines based on their research goals. In this section, we describe major bioinformatics steps for typical case-control RNA-Seq studies in human brain tissues, including read alignment, counting, differential expression, and pathway enrichment analysis (Fig. 1) .
Quality control of raw reads, read alignment, and counting
Quality control (QC) of RNA-Seq raw read data (FASTQ) involves evaluating GC bias, total number of reads, overall base quality score, rRNA content, duplication rates, and so forth. Assessment of sequencing performance is critical to the downstream bioinformatics analysis. Many popular tools, such as RNA-SeQC, 41 FastQC (http://www.bioinformatics.babraham.ac.uk/ projects/fastqc/) and NGSQC, 42 can be used for QC of RNA-Seq data.
In human transcriptome studies, raw reads are typically mapped to the well-annotated human reference genome. De novo assembly is less common and remains a challenge due to current short-read RNASeq-based approaches. The percentage of mapped reads is one of the most important quality parameters. It was estimated that around 70-90% of total reads should be mapped to the human genome. 43 A challenging task of this step is determining spliced reads across introns and exon-intron boundaries. The RNASeq Genome Annotation Assessment Project (RGASP) systematically evaluated six spliced aligners, including MapSplice, 44 GSNAP, 45 PALMapper, 46 ReadsMap, STAR, 47 and TopHat, 48, 49 and four alignment pipelines. 50 In this RGASP project, Engstrom et al. showed that GSNAP, GSTRUCT, MapSplice, and STAR perform better than the other approaches, 50 which is in agreement with a previous study conducted by Grant et al.
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Gene-level or transcript-level quantification is used to aggregate the reads aligned to each gene or transcript sequence. Programs such as featureCounts 52 or HTSeq-counts 53 are commonly used to perform gene-level quantification with the assistance of a Gene Transfer Format (GTF) or General Feature Format (GFF) file. Transcript-level quantification is more challenging since related transcripts share most of the reads. Cufflinks estimates transcripts level by using an expectation-maximization algorithm. 54 As one of the most popular tools, Cufflinks takes advantage of paired-end reads and could be used to perform transcripts assembly and identify novel isoforms.
Differential gene expression analysis
Identification of disease-associated DE genes is one of the ultimate goals in RNA-Seq studies of the postmortem human brain. Although there are many statistical programs for detecting DE genes or transcripts, no consensus has been reached regarding the best practices. Using two or more approaches may help reduce the bias induced by one single algorithm. 18 Comparison of methods for differential expression analysis has been conducted recently to address this issue. [55] [56] [57] [58] On average, algorithms based on negative binomial modeling, such as DESeq2 59, 60 and edgeR 61 have improved sensitivities and better control of false discovery rate. 58 Limma voom function 62 performs relatively well and runs faster than DESeq2 and edgeR. The poor performance of Cuffdiff and Cuffdiff2 indicates the challenges in the DE analysis at the transcript level. 43 In contrast to rodent-or cell-based data, principal component analysis of the RNA-Seq data in human brain tissues may not be able to show a separation between case and control groups. The sources of heterogeneity in human brain tissues include technical, compositional, and disease-related factors. Besides, complexity of bulk brain tissues may also result from the neural cell types it comprises. 63 Therefore, it is important to correct such cofounding factors like batch effects, race, sex, and other hidden variables. Statistical methods, such as ComBat 64 or 
Quantification of splice events
It was estimated that more than 90% of human genes undergo alternative splicing, 66 which contributes to the increased cellular complexity in higher eukaryotes. Pan et al. performed the first analysis of human tissue alternative splicing complexity with RNA-Seq data. 67 The human transcriptome analysis from the GTEx project demonstrated a more divergent alternative splicing in the brain. 7 Therefore, it is crucial to examine the splice events in the brain that may underlie the development of neuropsychiatry diseases. However, splice variant analysis from current short read RNA-Seq gene expression data is still challenging. A much deeper sequencing is required for detecting splice variants compared with DE genes. The quantification of splice events is indirect and requires probabilistic models due to the high similarity among isoforms. 68 Several computational tools are currently available to identify alternative splicing events, such as MISO, 69 MATS, 70 DiffSplice, 71 and SGSeq. 68 These tools allow scientists to identify splicing changes that exceed a given threshold for each research project, and to examine the extreme 'switch-like' differential alternative splicing pattern.
Gene co-expression network analysis
Gene co-expression networks construction is a common downstream analysis to study correlation patterns of genes across RNA-Seq samples, and infer gene function and gene-disease associations. 72 Weighted gene correlation network analysis (WGCNA) is the most popular package for coexpression analysis and the first co-expression tool to be applied to RNA-Seq gene expression data. 73 WGCNA can be used to identify co-regulated modules of highly correlated genes. The gene expression profiles of each module are represented by an eigengene, which will be further used to evaluate the association between the module and external numerical or categorical phenotype. 73 WGCNA also identifies hub genes based on intramodular connectivity (k IM ) or eigengene-based connectivity (k ME ).
In addition, pathway enrichment analysis can be performed to obtain a functional overview of modules. These approaches have been successfully applied in the analysis of brain transcriptome profiles of alcohol abusers 21 and bipolar subjects. 23 
Pathway analysis
The last step in a typical case-control RNA-Seq study is usually the functional overview of diseaseassociated DE genes. Pathway enrichment methods mainly fall into two major categories. The first approach is based on significant DE genes identified from the above steps. An overrepresentation test adopting the hypergeometric algorithm is performed by using a list of DE genes against the whole transcriptome. The other popular approach is the gene set enrichment analysis (GSEA) developed by Subramanian et al. 74 GSEA takes advantage of continuous expression changes information from all transcribed genes, and determines whether a set of related genes shows statistically significant, coordinated differences between case and control groups. Pathway analyses of the RNA-Seq study depend on the sufficient pathway annotation databases, such as the Kyoto Encyclopedia of Genes and Genomes (KEGG) PATHWAY database, 75 Gene Ontology, 76 Reactome, 77 and so forth. Tools such as Enrichr, 78 DAVID, 79 and commercial software like GeneGo and Ingenuity Pathway Analysis allow functional enrichment analysis against various pathway databases.
CONCLUSIONS AND FUTURE DIRECTIONS
Although using post-mortem human brains poses several challenges, such as limited sample size and cofounding factors, human brain tissue remains the gold standard to study brain disorders. It is evident that efforts like the establishment of brain banks have substantially improved the quality of these studies. RNA-Seq has become the standard approach for interrogating whole genome expression profiles in the human brain. However, challenges still exist, as discussed in this review. Care should be taken to control tissue and RNA quality as well as disease diagnosis of post-mortem brain samples. Choosing an optimal sample size, sequencing depth, and defining appropriate experimental design parameters are also critical to minimize bias and unwanted noise induced by the RNA-Seq technology. The ultimate choice of the RNA-Seq data analysis pipeline should take into consideration the study goals and characteristics of the human brain transcriptome.
Progress is likely to be enhanced by the use of newer technologies, such as single-cell RNA sequencing, which is used to capture accurate quantitative transcriptome in individual neurons. 63, 80 Highthroughput sequencing data analysis requires certain programing skills and high-performance computing systems. 81 Therefore, there is an urgent need for developing high-performance platforms and tools. It is reasonable to believe that improvements in RNASeq technology and availability of well-characterized brain specimens will significantly advance our understanding of complex neurological disorders.
RNA-Seq provides exciting opportunities for improving diagnosis and treatment of neurological diseases. In clinical neuroscience studies, integrative whole genome sequencing and transcriptome sequencing will provide additional information for functional role of mutated genes. 82 Furthermore, RNA-Seq helps prioritize DNA variants and detect splicing events. The development of pharmacotherapies that interrupt or reverse transcriptome changes caused by diseased states would be beneficial to the treatment of neuropsychiatric diseases.
